Syros Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch SYRS and buy or sell other stocks, ETFs, and their options commission-free!

About SYRS

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. 

CEO
Nancy A. Simonian
CEONancy A. Simonian
Employees
124
Employees124
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2011
Founded2011
Employees
124
Employees124

SYRS Key Statistics

Market cap
12.60K
Market cap12.60K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
5.31M
Average volume5.31M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$5.22
52 Week high$5.22
52 Week low
$0.65
52 Week low$0.65

Stock Snapshot

Syros Pharmaceuticals(SYRS) stock is priced at $0.00, giving the company a market capitalization of 12.6K.

Syros Pharmaceuticals(SYRS) stock opened on 2026-03-18 at —. The price climbed to — and dipped to —.

Syros Pharmaceuticals(SYRS) shares are trading with a volume of 0, against a daily average of 5.31M.

During the past year, Syros Pharmaceuticals(SYRS) stock moved between $0.65 at its lowest and $5.22 at its peak.

During the past year, Syros Pharmaceuticals(SYRS) stock moved between $0.65 at its lowest and $5.22 at its peak.

People also own

Based on the portfolios of people who own SYRS. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.